Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 17,108 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Kidney Transplantation
Interventions: mycophenolate mofetil [CellCept], Cyclosporine or tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Primary Hyperoxaluria Type 1, PH1
Interventions: YOLT-203, Placebo; Genetic · Drug
Lead sponsor: YolTech Therapeutics Co., Ltd; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: ESRD
Interventions: Sodium Restriction; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Female Contraception
Interventions: Transdermal system containing progestin; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 56
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 40 more

Conditions: Mitral Valve Regurgitation
Interventions: Mitral valve repair, Transcatheter edge-to-edge repair; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 19 more

Conditions: T-Cell and NK-Cell Neoplasm
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 6 more

Conditions: Hepatitis C
Interventions: Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo; Biological · Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more

Conditions: Ovarian Cancer, Sarcoma
Interventions: dolastatin 10; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 4
States / cities: Denver, Colorado • Rochester, Minnesota • Columbus, Ohio + 1 more

Conditions: Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson's Disease
Interventions: Lab Assay for seven genetic variants for Parkinson's Disease; Device
Lead sponsor: Parkinson's Foundation; Other
Eligibility: 18 Years and older
Enrollment: 35,382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 63
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 50 more

Conditions: Cutaneous Lupus Erythematosus
Interventions: CC-11050, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more

Conditions: LAM, Lymphangioleiomyomatosis
Interventions: Sirolimus; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 5 more

Conditions: Apical Periodontitis
Interventions: Leukocyte and Platelet Rich Fibrin; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myelofibrosis (MF)
Interventions: Navitoclax, Ruxolitinib, Best Available Therapy (BAT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 41
States / cities: Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: High Blood Pressure
Interventions: Yoga exercise program, Blood pressure education/walking program; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Aspergillosis, Invasive Fungal Infections
Interventions: isavuconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin human, insulin lispro, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg, CR845 1 mcg/kg, CR845 1.5mcg/kg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 29
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Long Beach, California + 23 more

Conditions: Oncology
Interventions: Once time de-identified Qualtrics survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder
Interventions: Vibegron; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more

Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 2 more

Conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions: palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 35
States / cities: San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more

Conditions: Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 254
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more

Search by objective public record fields.

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

A Global Study of the PETAL Consortium

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

Parkinson's Foundation PD GENEration Genetic Registry

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

Evaluation of Periapical Healing Following Endodontic Microsurgery With Leukocyte and Platelet Rich Fibrin (L-PRF)

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Lifestyle Modification and Blood Pressure Study

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Assessing Perceptions of ML Explanations by Medical Oncologists

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial